<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Theophylline poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Theophylline poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Theophylline poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Holly Perry, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Ruha, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic will review the clinical features and management of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> overdose in infants, children, and adults.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Historically, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> has had two primary indications: as a bronchodilator for patients with asthma or chronic obstructive pulmonary disease and as an agent to treat apnea and bradycardia in premature newborns.</p><p>Nevertheless, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> remains an important drug:</p><p class="bulletIndent1"><span class="glyph">●</span>It is still used within the United States to treat apnea and bradycardia of prematurity and remains widely used in countries outside the United States as a bronchodilator.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other indications that have been explored include treatment of postlumbar puncture headache [<a href="#rid1">1</a>], prevention of nephropathy due to contrast agents [<a href="#rid2">2</a>], lymphedema [<a href="#rid3">3</a>], out-of-hospital cardiac arrest [<a href="#rid4">4</a>], prevention of obstructive sleep apnea [<a href="#rid5">5</a>], reversal of bradycardia in spinal cord injury patients [<a href="#rid6">6</a>], and hyposmia (loss of smell) [<a href="#rid7">7</a>].</p><p></p><p>Most <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> exposures are unintentional and occur in patients over 20 years of age [<a href="#rid8">8</a>]. Oral overdose of sustained release preparations is most commonly reported [<a href="#rid9">9,10</a>]. As therapeutic use has declined, the frequency of serious theophylline poisoning has also decreased. Over eight years, the number of annual cases of theophylline exposure reported to United States poison control centers decreased from 1395 to 347 [<a href="#rid11">11,12</a>]. In the United States during the period of 1985 to 1995, theophylline poisoning requiring hemodialysis or hemoperfusion accounted for 49 cases per one million poison center calls, versus only 6 cases per one million poison center calls from 1996 to 2005 [<a href="#rid13">13</a>]. Only 140 exposures and one death were reported to United States poison control centers in 2020 [<a href="#rid14">14</a>]. However, life-threatening theophylline poisoning remains a concern, especially in older adults.</p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span></p><p class="headingAnchor" id="H4"><span class="h2">Therapeutic serum levels and dosing</span><span class="headingEndMark"> — </span>The therapeutic steady state serum concentration for <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> ranges from 10 to 20 mcg/mL (56 to 111 micromol/L) when used to treat asthma. Other indications have lower therapeutic ranges. Theophylline has a narrow clinical therapeutic index (ratio of 50 percent toxic dose to 50 percent effective dose) of 1 to 1.5. Theophylline is available as an elixir, extended release capsule, and controlled release tablet. </p><p>The intravenous form of the drug, <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a>, is a 2:1 complex of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> and ethylenediamine. It contains approximately 80 percent theophylline by weight. </p><p><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> metabolism, and consequently half-life, shows a wide variation as a function of age. Clearance is low at birth, increases dramatically after six months of age, peaks at age two years, and then gradually falls to adult levels by age 16 years. Thus, intravenous and oral maintenance dosing is highly variable. In addition, the narrow therapeutic index requires frequent evaluation of serum theophylline concentration in individual patients to ensure safe administration. </p><p class="headingAnchor" id="H5"><span class="h2">Toxic dose</span><span class="headingEndMark"> — </span>Manifestations of acute toxicity (eg, vomiting) may occur with ingested or administered doses as low as 7.5 mg/kg (expected peak level 15 mcg/mL [84 micromol/L]).</p><p>Since chronic <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> toxicity often results from accumulation of the drug due to saturation of the metabolic pathways, decreased clearance, and/or inhibition by coadministered drugs or herbal medications, serious toxicity may occur despite regular daily dosing within the normal range for weight. (See <a class="local">'Kinetics'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a>'s effects arise from antagonism of adenosine receptors and indirect adrenergic activity.</p><p>Adenosine receptors are widely distributed throughout the body. Antagonism of these receptors has both therapeutic and toxic effects, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Bronchodilation</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac arrhythmias</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral vasoconstriction [<a href="#rid15">15-17</a>]</p><p></p><p><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> intoxication has also been shown to be associated with increased plasma catecholamines in animal models [<a href="#rid18">18,19</a>] as well as in case series of human victims of theophylline intoxication [<a href="#rid20">20,21</a>]. The magnitude of catecholamine elevation and the specific catecholamines released vary depending on the type of intoxication:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute intoxication has been shown to be associated with <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> concentrations four- to eightfold higher than controls and <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> concentrations four- to tenfold higher than controls [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the few patients with chronic overdose who have been studied, <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> and <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> levels were elevated compared with normal patients [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At toxic concentrations, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> is a phosphodiesterase inhibitor. Phosphodiesterase inhibition increases levels of cyclic adenosine monophosphate, which augments beta-adrenergic effects. Adrenergic hyperstimulation results in the metabolic abnormalities frequently seen with theophylline intoxication (eg, hypokalemia, hyperglycemia, metabolic acidosis). Excess catecholamines may also predispose to arrhythmias as well as contribute to hypotension through beta-adrenergic-mediated vasodilation.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">KINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> is notable for having a low volume of distribution, high absorption, and highly variable metabolism that is altered by age, viral illness, cardiac failure, and liver disease. Chronic intoxication is typically due to theophylline's complicated metabolism. At levels only slightly above therapeutic range, its kinetics converts from first order to zero order. This conversion causes small changes in either dosing or metabolism to result in large changes in serum concentration. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absorption</strong> – When taken orally, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> is 80 to 100 percent absorbed, and there is no significant first-pass metabolism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein binding</strong> – <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> is 50 to 65 percent protein bound in the circulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Volume of distribution</strong> – <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> has a relatively small volume of distribution (Vd) of 0.45 L/kg. The Vd is slightly larger at the extremes of age [<a href="#rid22">22</a>]. These factors allow the clinician to accurately estimate the anticipated peak level following an acute ingestion of theophylline. For every 1 mg/kg ingested, the peak level is expected to rise 2 micrograms/mL. Similarly, since 1 mg of <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a> is equivalent to 0.8 mg of theophylline, each 1.2 mg/kg administered intravenously is anticipated to raise the serum level of theophylline 2 microgram/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism</strong> – <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> metabolism and half-life show a wide variation as a function of age. Clearance is low at birth, increases dramatically after six months of age, peaks at age two years, and then gradually falls to adult levels by age 16 years.</p><p></p><p class="bulletIndent1">In newborns, 50 percent is excreted unchanged in the urine with the remainder being metabolized in the liver [<a href="#rid22">22</a>]. Because the mixed function oxidase system is not mature, N-methylation to caffeine is an important metabolic pathway. Caffeine accumulates in newborns on <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> treatment [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1">As the mixed function oxidase system develops, approximately 90 percent is metabolized through that system by CYP1A2, CYP2E1, and CYP3A4. Changes in metabolism translate into a half-life, which is a function of age. In premature infants, half-life is 30 hours, falling to 25 hours in term infants, three hours in young children, and gradually rising to an adult half-life of eight hours by age 16 years [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">For all ages, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> metabolism follows Michaelis-Menten (saturable) kinetics. Over the therapeutic range, metabolism follows first order kinetics (ie, 50 percent of the drug is metabolized during one half-life). Slightly above the therapeutic range, however, the kinetics shift to zero order (ie, a set amount of drug is metabolized per unit time) and small increases in theophylline dosing can lead to rapid increases in serum concentrations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – Metabolism of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> is affected by any process that alters activity of the cytochrome oxidases CYP1A2, CYP2E1, and CYP3A4 located in the liver. These isoenzymes have been shown to be inhibited by a wide variety of intercurrent diseases such as upper respiratory infections associated with fever, as well as a large number of pharmaceuticals including <a class="drug drug_general" data-topicid="9265" href="/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> [<a href="#rid22">22</a>]. Herbal preparations (eg, St. John's wort) have also been shown to interfere with theophylline metabolism  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 1</a>) [<a href="#rid24">24</a>]. Concurrent use of theophylline and a number of drugs (eg, cimetidine) has been shown to be associated with a significantly increased risk of hospitalization [<a href="#rid25">25</a>]. Thus, prior to prescribing a new agent to a patient who is chronically on theophylline, it is prudent to check that there is no documented inhibition of the mixed function oxidase system.</p><p></p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES OF OVERDOSE</span><span class="headingEndMark"> — </span>A rapid overview provides the common clinical findings after <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning  (<a class="graphic graphic_table graphicRef61581" href="/d/graphic/61581.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H9"><span class="h2">History</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> intoxication is classified as acute or chronic. It is one of a handful of drugs where the method of intoxication (ie, acute versus chronic) has significant implications both for clinical presentation as well as for management. (See <a class="local">'Extracorporeal removal'</a> below.)</p><p>Three common scenarios that result in <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> intoxication include:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient intentionally overdoses acutely either as an exploratory ingestion (toddler) or suicide attempt (school age and older).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An inadvertent substitution of <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a> for another medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient on maintenance therapy develops toxic levels secondary to a decrease in <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> metabolism, usually due to addition of another drug or an intercurrent illness.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Physical findings</span><span class="headingEndMark"> — </span>Symptoms can be grouped into five major areas: metabolic, musculoskeletal, gastrointestinal, cardiac, and neurologic. The spectrum of toxicity varies widely. Patients suffering from chronic intoxication may have few initial symptoms but are at risk for major complications including arrhythmias and seizures. Minor symptoms include metabolic abnormalities, coarse muscle tremor, vomiting, and abdominal pain. Seizures, hypotension, and arrhythmias are the life-threatening symptoms seen following intoxication. Death typically results from intractable ventricular arrhythmias [<a href="#rid26">26</a>].</p><p>Morbidity correlates with serum <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> concentration in patients with acute toxicity but <strong>not</strong> in patients with chronic toxicity where extremes of age are more predictive. (See <a class="local">'Ancillary studies'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective observational study of 249 children and adults with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> overdose, major toxicity (seizures or cardiac arrhythmias) was significantly associated with serum theophylline concentration in patients with acute overdose (n = 119) but not in patients with chronic overdose (n = 92). Age greater than 60 years was the best predictor of serious toxicity in patients with chronic toxicity [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic intoxication was the primary risk factor for life-threatening events in a prospective observational study of 125 pediatric victims of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> toxicity [<a href="#rid27">27</a>]. Victims of chronic intoxication who suffered life-threatening events were significantly younger (1.6 versus 8.0 years; p&lt;0.001) but did not have higher peak theophylline levels. In contrast, those children who were victims of an acute overdose with life-threatening events had significantly higher peak serum theophylline concentrations (100 versus 57 micrograms/mL [550 versus 319 micromols/L]; p&lt;0.004), and age was not a risk factor [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Metabolic</span><span class="headingEndMark"> — </span>Hypokalemia and hyperglycemia are seen frequently in patients with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> intoxication (79 percent acute versus 43 percent chronic) [<a href="#rid9">9</a>]. They result from adrenergic stimulation and are rarely clinically important. Other metabolic abnormalities less commonly seen include metabolic acidosis [<a href="#rid28">28</a>], hypercalcemia [<a href="#rid29">29</a>], and hypophosphatemia [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Musculoskeletal</span><span class="headingEndMark"> — </span>Coarse tremor is another minor symptom that is frequently noted [<a href="#rid31">31</a>] and thought to result from disturbances in skeletal muscle homeostasis of potassium. Rhabdomyolysis has also been noted in 4 to 7 percent of adults with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> toxicity [<a href="#rid9">9,30,32</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Gastrointestinal</span><span class="headingEndMark"> — </span>Vomiting or abdominal pain occurs almost universally following acute overdose (79 to 97 percent) [<a href="#rid30">30,33</a>] and less commonly following chronic overmedication (40 to 66 percent) [<a href="#rid9">9,30</a>]. Vomiting tends be persistent [<a href="#rid34">34</a>] and difficult to control [<a href="#rid10">10</a>]. It may interfere with the ability to administer multiple-dose activated charcoal successfully and can be forceful enough to result in a Mallory-Weiss tear [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/2272.html" rel="external">"Mallory-Weiss syndrome"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Neurologic</span><span class="headingEndMark"> — </span>Seizures are the most concerning of the neurologic symptoms following <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning and may be the first sign of toxicity, particularly in infants or in patients with chronic poisoning. Seizures are most frequently multiple and generalized, focal seizures and simple complex with secondary generalization also occur, most commonly in patients with chronic toxicity [<a href="#rid30">30</a>]. Several authors have suggested that underlying neurologic abnormalities may be a risk factor for development of seizures [<a href="#rid35">35,36</a>].</p><p>Seizures are a concerning finding in adults because they can be difficult to control [<a href="#rid30">30</a>], may have significant morbidity, and, in older adults, mortality as high as 50 percent [<a href="#rid37">37-39</a>].</p><p>In contrast, case series indicate that most seizures in children are easily controlled by benzodiazepines and occur in approximately 5 percent of patients [<a href="#rid27">27,33,40</a>]. Although there was no long-term follow-up to evaluate for neurological sequelae reported for these children, our experience suggests that full recovery should be expected if children do not experience prolonged hypoxemia or hypotension.</p><p>Lethargy and visual hallucinations are less common neurologic findings in patients with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Cardiovascular</span><span class="headingEndMark"> — </span>With the exception of sinus tachycardia, which is seen in most patients [<a href="#rid9">9,30,33</a>], cardiac manifestations of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> toxicity appear to be quite different between adults and children:</p><p class="bulletIndent1"><span class="glyph">●</span>Intractable ventricular arrhythmias are the most common cause of death in adults and occur in 2 to 20 percent of patients studied [<a href="#rid9">9,26,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, children are most likely to have supraventricular tachycardia or multifocal premature ventricular or atrial contractions [<a href="#rid27">27,33,40</a>]. Transient alterations in blood pressure have also been reported [<a href="#rid33">33,40</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h1">ANCILLARY STUDIES</span><span class="headingEndMark"> — </span>The clinician should obtain the following studies on an emergency basis in patients with suspected <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning  (<a class="graphic graphic_table graphicRef61581" href="/d/graphic/61581.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a><strong> levels</strong> – If a sustained-release preparation has been ingested acutely, the theophylline level should be measured every two hours until it peaks and then every four hours up to 24 hours after ingestion. In situations where an unknown formulation was ingested, the clinician should always assume that a sustained-release preparation is the toxic agent. The wax-matrix found in many sustained-release preparations can result in bezoar formation with erratic and delayed absorption, sometimes with lethal consequences [<a href="#rid10">10,41</a>].</p><p></p><p class="bulletIndent1">In patients with chronic theophylline poisoning, once a peak elevated level is established, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> levels should be assessed on a daily basis until clinical signs resolve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum glucose</strong> – Hyperglycemia is found in the majority of patients with serious acute <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum electrolytes</strong> – Theophylline toxicity results in hypokalemia and metabolic acidosis with decreased serum bicarbonate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum calcium</strong> – <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> poisoning is associated with hypercalcemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram</strong> – An initial 12-lead electrocardiogram (ECG) is essential to evaluate for the presence of rhythm disturbance and, in adult patients, evidence of myocardial ischemia. Continuous cardiac monitoring is also warranted.</p><p></p><p>Additional studies may be indicated depending on patient characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> level in patients who ingest <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> with intent for self-harm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum aspartate transferase (AST), alanine transferase (ALT), prothrombin time, and partial thromboplastin time in patients with suspected baseline alteration in liver function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid urine pregnancy test in postmenarcheal women.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum salicylate concentration, serum iron concentration, and urine screen for drugs of abuse in patients with an unknown ingestion and clinical findings suggestive of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning.</p><p></p><p class="headingAnchor" id="H4239183680"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of acute <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning is suspected in patients with a history of ingestion or access to theophylline and/or clinical findings of overdose including vomiting, agitation, tremors, seizures, tachyarrhythmias, hypotension, or hypokalemia with metabolic acidosis. An elevated theophylline level confirms the diagnosis. </p><p>Patients with chronic intoxication may present with few overt symptoms despite a markedly elevated <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> level. Seizures may be the first clinical manifestation of toxicity in these patients. </p><p class="headingAnchor" id="H3216677968"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> toxicity should be considered in any patient presenting with seizures, agitation, tachyarrhythmias, hypotension, or persistent vomiting, particularly if there is hypokalemia and hyperglycemia. Other toxic agents to consider in patients with these symptoms include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-2 adrenergic agonists</strong> – Agents such as <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a> (also known as salbutamol), clenbuterol, and <a class="drug drug_general" data-topicid="9977" href="/d/drug information/9977.html" rel="external">terbutaline</a> also cause vomiting, sinus tachycardia, muscle tremor, hypokalemia, hyperglycemia, and metabolic acidosis in overdose. However, seizures and cardiac arrhythmias are rare [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cocaine and amphetamines</strong> – Cocaine or amphetamine intoxication may cause agitation, seizures, cardiac arrhythmias, and tremulousness. However, hypertension, diaphoresis, and hyperthermia are additional features of severe poisoning with these agents that are not commonly seen in patients with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning. Furthermore, vomiting, an early and prominent finding in acute theophylline overdose, is not commonly seen in patients with cocaine or amphetamine intoxication. (See  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication", section on 'Examination findings associated with intoxication and complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron</strong> – Vomiting is an early and consistent sign of iron poisoning and may be accompanied by leukocytosis, hyperglycemia, metabolic acidosis, sinus tachycardia, and hypotension. Severe iron overdose typically causes coma and cardiogenic shock. Seizures are less common. (See  <a class="medical medical_review" href="/d/html/6498.html" rel="external">"Acute iron poisoning"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Salicylates</strong> – Vomiting, sinus tachycardia, hypotension, altered mental status with coma or seizures, and hyperglycemia are potential findings after salicylate poisoning. However, salicylates typically cause a respiratory alkalosis with marked tachypnea soon after an acute overdose. Hyperthermia may be seen in patients with severe poisoning. (See  <a class="medical medical_review" href="/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Recommendations for care of children and adults with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning are derived from case series and reports. Management is determined by signs of poisoning, the peak serum theophylline concentration following acute overdose, and, in chronic overdoses, physical findings and age. Management is summarized in the rapid overview  (<a class="graphic graphic_table graphicRef61581" href="/d/graphic/61581.html" rel="external">table 2</a>).</p><p>Good outcomes in these patients depend on supportive care that focuses on the metabolic, cardiovascular, and neurologic manifestations of toxicity and timely use of elimination enhancement.</p><p class="headingAnchor" id="H19"><span class="h2">Supportive care</span></p><p class="headingAnchor" id="H20"><span class="h3">Hypokalemia and metabolic acidosis</span><span class="headingEndMark"> — </span>Hypokalemia and metabolic acidosis arise from catecholamine excess and are rapidly reversible by appropriate enhancement of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> elimination. (See <a class="local">'Mechanism of action'</a> above.)</p><p>We suggest potassium supplementation (eg, 40 mEq KCL/L in intravenous fluids run at 1 to 1.5 times maintenance) for hypokalemic <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoned patients with potassium &lt;3 mEq/L or with ventricular arrhythmias [<a href="#rid43">43</a>]. In patients with theophylline poisoning, hypokalemia typically reflects a shift of potassium into the tissues rather than total body potassium depletion. Thus, the need for potassium supplementation decreases as the theophylline concentration decreases, and close monitoring of serum potassium levels and reduction of potassium supplementation is important. Mild hyperkalemia frequently results from potassium replacement [<a href="#rid10">10</a>].</p><p>Metabolic acidosis after <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning rarely requires specific intervention (eg, administration of <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a>), unless severe (eg, pH &lt;7).</p><p class="headingAnchor" id="H21"><span class="h3">Vomiting</span><span class="headingEndMark"> — </span>Emesis in patients with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning is frequently persistent and difficult to treat but must be controlled to permit administration of multiple-dose activated charcoal [<a href="#rid44">44</a>].</p><p>We suggest that patients with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning and persistent vomiting receive high-dose <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> (initial dose: 0.15 mg/kg up to 16 mg intravenously). This recommendation is based on case reports that describe reduced vomiting in patients who received ondansetron after standard antiemetics, including phenothiazines and <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, were ineffective [<a href="#rid45">45,46</a>].</p><p><a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">Metoclopramide</a> intravenously may be used in addition to <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> or as an alternative agent. If used as a single agent, however, high doses (up to 0.5 to 1 mg/kg, maximum dose 50 mg) may be necessary [<a href="#rid47">47</a>]. High doses have been associated with acute dystonic reactions and may be treated with <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>.</p><p>In addition to an antiemetic, we suggest that patients with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning and vomiting receive the H2 blocker <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a>. H2 blockers are an important adjunct because they decrease theophylline-induced gastric acid hypersecretion [<a href="#rid48">48</a>]. Famotidine has the theoretical advantage over <a class="drug drug_general" data-topicid="9265" href="/d/drug information/9265.html" rel="external">cimetidine</a> in not interfering with theophylline metabolism at cytochrome 3A4.</p><p class="headingAnchor" id="H22"><span class="h3">Hypotension</span><span class="headingEndMark"> — </span>Hypotension is caused by beta-2 adrenergic stimulation and vasodilation. Initial treatment consists of rapid infusion of isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (initial dose: 20 mL/kg, up to 1 L) and treatment of any cardiac arrhythmias  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef129655" href="/d/graphic/129655.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef130747" href="/d/graphic/130747.html" rel="external">algorithm 3</a>). (See <a class="local">'Cardiac arrhythmias'</a> below.)</p><p>If hypotension is not responsive to fluid administration and/or treatment of cardiac arrhythmias, a pure alpha-adrenergic agonist (such as <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a>) or a predominant alpha-adrenergic agonist (such as <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a>) should be used. Selective beta-adrenergic agonists (such as <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a>) and mixed alpha-beta adrenergic agonists (such as <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>) should not be used, as many of the cardiovascular derangements of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> toxicity are caused by cellular effects that may be exacerbated by beta-2 adrenergic agonism.</p><p>For patients refractory to the above measures, hypotension may also be reversed by <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> [<a href="#rid18">18,49</a>] or other beta-adrenergic antagonists such as <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>. Propranolol must be used cautiously in patients with asthma or chronic obstructive pulmonary disease. The decision to use a beta-adrenergic antagonist to treat a hypotensive patient is very difficult, and should only be made in consultation with a medical toxicologist. In the United States, call 1-800-222-1222 to be connected to the nearest poison control center. Contact information for poison centers around the world is provided separately. (See <a class="local">'Additional resources'</a> below.)</p><p class="headingAnchor" id="H23"><span class="h3">Cardiac arrhythmias</span><span class="headingEndMark"> — </span>Arrhythmias should be treated initially according to advanced cardiac life support or pediatric advanced life support recommendations  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef130747" href="/d/graphic/130747.html" rel="external">algorithm 3</a>). Arrhythmias are much more common in adults, especially older adults, than in children [<a href="#rid9">9,26,40</a>]. Supraventricular tachycardia and other atrial tachycardias are the most common arrhythmias induced by <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> [<a href="#rid26">26</a>]. Ventricular arrhythmias are rare in children [<a href="#rid50">50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supraventricular tachycardia</strong> – Pharmacologic or electrical cardioversion should be performed according to advanced cardiac life support or pediatric advanced life support recommendations  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef130747" href="/d/graphic/130747.html" rel="external">algorithm 3</a>).</p><p></p><p class="bulletIndent1">Rapid intravenous infusion of adenosine (0.1 mg/kg, maximum initial: dose 6 mg) has reversed theophylline-induced supraventricular tachycardia (SVT) [<a href="#rid51">51</a>] and is recommended as first-line therapy by some experts [<a href="#rid43">43,47</a>]. Given that <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> is a potent adenosine antagonist, however, treatment failure should be anticipated. Adenosine's ultra-short half-life may also leave the patient susceptible to recurrent SVT. In addition, adenosine poses a risk for bronchoconstriction in patients with asthma or chronic obstructive pulmonary disease [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1">Alternatively, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>, a selective beta-1 antagonist, is safe for use in theophylline-poisoned patients with asthma and has also been used effectively to terminate supraventricular tachycardia [<a href="#rid52">52,53</a>]. In children, the dose is 100 to 500 mcg/kg, intravenously, given over one minute. In adults, rapid intravenous infusion of 500 mcg/kg over one minute is followed by a continuous infusion of 50 mcg/kg infusion for at least four minutes.</p><p></p><p class="bulletIndent1">In adults, intravenous therapy with calcium channel blockers (eg, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, initial dose 2.5 to 5 mg; or <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> 0.25 mg/kg, typical initial dose 20 mg) may be useful but should be administered with caution in patients with hypotension. (See  <a class="medical medical_review" href="/d/html/951.html" rel="external">"Calcium channel blockers in the treatment of cardiac arrhythmias", section on 'Supraventricular tachycardia'</a>.)</p><p></p><p class="bulletIndent1">Calcium channel blockers should be <strong>avoided</strong> in infants and children under three years of age with SVT because these agents may cause hypotension, myocardial depression, sudden cardiovascular collapse, and death. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventricular arrhythmias</strong> – Patients with ventricular fibrillation or pulseless ventricular tachycardia should receive defibrillation and medication administration according to the advanced cardiac life support or pediatric advanced life support recommendations  (<a class="graphic graphic_algorithm graphicRef129942" href="/d/graphic/129942.html" rel="external">algorithm 4</a> and <a class="graphic graphic_algorithm graphicRef129983" href="/d/graphic/129983.html" rel="external">algorithm 5</a>).</p><p></p><p class="bulletIndent1">In patients with stable ventricular tachycardia, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> or <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> may be administered. Selective beta adrenergic antagonists (eg, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>) or, in patients without asthma or chronic obstructive pulmonary disease, nonselective beta adrenergic antagonists (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>) are adjunct therapies that target the catecholamine excess seen in patients with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> overdose. In addition, patients with ventricular arrhythmias and hypokalemia warrant intravenous potassium supplementation. (See <a class="local">'Hypokalemia and metabolic acidosis'</a> above.)</p><p></p><p class="bulletIndent1">Although successful treatment of theophylline-induced ventricular arrhythmias with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> has not been described, this approach seems reasonable given that intravenous amiodarone has a rapid onset of an antiadrenergic effect. (See  <a class="medical medical_review" href="/d/html/926.html" rel="external">"Amiodarone: Clinical uses"</a>.)</p><p></p><p class="headingAnchor" id="H24"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>Patients with seizures require treatment for status epilepticus as described in the algorithm for children  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 6</a>) and adults  (<a class="graphic graphic_algorithm graphicRef74649" href="/d/graphic/74649.html" rel="external">algorithm 7</a>) and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a> and  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults"</a>.) </p><p><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> or <a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">fosphenytoin</a> should be <strong>avoided</strong> in all patients with theophylline-induced seizures because it has not been effective at terminating seizures in human victims [<a href="#rid30">30</a>] and, in animal models, leads to increased mortality [<a href="#rid54">54</a>].</p><p>Patients with the following characteristics may also benefit from prophylactic anticonvulsant therapy with either benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>) or <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> because of the high likelihood that seizures will develop [<a href="#rid22">22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of neuromuscular excitability</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute overdose with serum <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> concentration ≥80 micrograms/mL (448 micromol/L)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants &lt;6 months old or adults ≥65 years of age with chronic intoxication and a serum <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> concentration ≥30 micrograms/mL (168 micromol/L)</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> binds well to activated charcoal (AC). Theophylline also is cleared more rapidly from the blood in patients who receive multiple-dose AC. (See <a class="local">'Multiple-dose activated charcoal'</a> below.)</p><p>For all patients with an acute <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> overdose, we recommend an initial dose of AC (1 g/kg, maximum dose: 50 g) by mouth or, after consultation with a medical toxicologist, nasogastric tube  (<a class="graphic graphic_table graphicRef61581" href="/d/graphic/61581.html" rel="external">table 2</a>). AC should be withheld in patients who have altered mental status and may not be able to protect their airway, unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving AC.</p><p>The recommendation of AC administration following <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> overdose derives from direct evidence that multiple doses of AC increase the clearance of theophylline from the blood stream and appear to shorten the duration of toxicity. (See <a class="local">'Multiple-dose activated charcoal'</a> below.)</p><p>There is also indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications. Because of adverse effects, such as vomiting and dehydration, the combination of a cathartic (eg, <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a>) and AC should be used sparingly, if at all, and only a single dose of a cathartic should be given to any patient. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Cathartics'</a> and  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p>There is no role for gastric emptying by gastric lavage or by syrup of ipecac-induced emesis in patients who ingest <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>. Randomized controlled trials show minimal benefit and possible risk to patients who undergo gastric emptying after poisoning. (See  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient"</a>.)</p><p>The use of whole bowel irrigation (WBI) in patients who have ingested sustained-release preparations of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> is controversial. The American Academy of Clinical Toxicologists and the European Association of Poison Control Centers and Clinical Toxicologists determined that a toxic ingestion of a sustained release preparation is a possible indication for WBI [<a href="#rid55">55</a>]. However, animal models of WBI for sustained release theophylline ingestion did not demonstrate any benefit [<a href="#rid56">56,57</a>]. Because WBI requires a nasogastric tube and may also promote vomiting, we do not routinely use it in the treatment of theophylline poisoning.</p><p class="headingAnchor" id="H3590405044"><span class="h2">Elimination enhancement</span><span class="headingEndMark"> — </span>After gastrointestinal decontamination, elimination enhancement is indicated for patients with symptomatic <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning and for asymptomatic patients with significantly elevated theophylline levels regardless of symptoms.</p><p class="headingAnchor" id="H26"><span class="h3">Multiple-dose activated charcoal</span><span class="headingEndMark"> — </span>For patients with symptomatic <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning, we recommend multiple-dose activated charcoal (MDAC)  (<a class="graphic graphic_table graphicRef61581" href="/d/graphic/61581.html" rel="external">table 2</a>). When administering MDAC, the initial dose of 1 g/kg of activated charcoal with or without <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> is followed by 0.5 to 1 g/kg of activated charcoal in aqueous suspension <strong>without</strong> sorbitol every two to four hours. High-dose antiemetic therapy and use of a nasogastric tube are frequently necessary to ensure effective administration. Multiple doses of sorbitol may produce <strong>profound</strong> dehydration and life-threatening hypernatremia, and inadvertent administration of multiple doses of sorbitol must be avoided. (See  <a class="medical medical_review" href="/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Multiple-dose activated charcoal'</a> and  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Cathartics'</a>.)</p><p>The recommendation for MDAC is based on the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>A crossover trial in six healthy adults who received intravenous <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a> demonstrated that repeated doses of AC reduced the serum half-life for <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> by 50 percent [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A crossover trial in seven healthy adults who received intravenous <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a> found that repeated doses of AC significantly reduced the serum half-life for <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> from 10.2 to 4.6 hours [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MDAC markedly reduced the half-life of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> in four severely poisoned adults with theophylline overdose including a 72-year-old man with a serum theophylline of 31 mcg/mL (172 micromol/L), cardiac arrhythmias, and seizures whose half-life decreased from 34.4 to 5.7 hours with rapid resolution of clinical toxicity after MDAC therapy [<a href="#rid59">59</a>].</p><p></p><p>In addition to directly binding <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> in the gut, the effect of MDAC appears to occur through a process termed "gastrointestinal dialysis": promotion of back diffusion of theophylline from the blood to the intestinal lumen where it is bound to charcoal. This mechanism of action is supported by the ability of MDAC to decrease the half-life of theophylline despite intravenous administration in humans and by the impact of luminal AC on intestinal theophylline diffusion in a rat model [<a href="#rid50">50,59,60</a>].</p><p class="headingAnchor" id="H27"><span class="h3">Extracorporeal removal</span><span class="headingEndMark"> — </span>In patients with severe life-threatening <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning (exhibiting seizures, cardiac arrhythmias, or hypotension) or with markedly elevated theophylline levels, regardless of symptoms  (<a class="graphic graphic_table graphicRef138597" href="/d/graphic/138597.html" rel="external">table 3</a>) and those with symptomatic theophylline poisoning but without a functioning gastrointestinal tract, we recommend extracorporeal removal (ECR) [<a href="#rid26">26,61</a>]. For patients receiving ECR, we suggest high efficiency hemodialysis rather than hemoperfusion or continuous kidney replacement therapy. Whenever possible, ECR should be used to treat patients with severe theophylline poisoning <strong>before</strong> seizures or cardiac arrhythmias develop because hemodialysis or hemoperfusion has <strong>not</strong> been shown to reliably terminate these life-threatening events [<a href="#rid62">62</a>]. When deciding about the initiation of ECR in patients with severe theophylline poisoning, we encourage consultation with a medical toxicologist or regional poison control center. (See <a class="local">'Additional resources'</a> below.)</p><p>Although high efficiency hemodialysis is strongly preferred, if it is not available or feasible, other modalities (such as hemoperfusion or continuous kidney replacement therapy) may be used instead. In neonates who are too ill to withstand hemodialysis, hemoperfusion, or continuous kidney replacement therapy, triple volume exchange transfusions may be effective [<a href="#rid63">63</a>]. Peritoneal dialysis removes <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> but too slowly to have a role in the treatment of theophylline poisoning [<a href="#rid64">64</a>].</p><p><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> has the physical characteristics (low volume of distribution without extensive protein binding) that make it amenable to ECR. The risk for developing life-threatening arrhythmias or seizures after theophylline overdose varies based on type of poisoning (acute versus chronic), serum theophylline concentration in acutely poisoned patients, and individual patient factors [<a href="#rid26">26,47,61,65,66</a>]. Historically, charcoal hemoperfusion has been considered as a treatment modality for theophylline toxicity. However, high efficiency hemodialysis is as effective as charcoal hemoperfusion for removing theophylline from the bloodstream, is safer, and is more readily available [<a href="#rid52">52,62,67</a>]. </p><p class="headingAnchor" id="H30"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H1809895615"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H270827695"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid overview</strong> – A rapid overview  (<a class="graphic graphic_table graphicRef61581" href="/d/graphic/61581.html" rel="external">table 2</a>) provides the clinical features, diagnostic evaluation, and initial management of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a>'s toxic effects arise from antagonism of adenosine receptors and indirect adrenergic activity. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxic dose</strong> – After acute overdose, manifestations of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> toxicity may occur with an ingested or administered dose &gt;7.5 mg/kg (expected peak serum theophylline concentration &gt;15 mcg/mL [84 micromol/L]). Patients with chronic toxicity can have serious toxicity despite regular daily dosing within the normal range for weight. (See <a class="local">'Toxic dose'</a> above and <a class="local">'Clinical features of overdose'</a> above and <a class="local">'Ancillary studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Clinical features of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning include (see <a class="local">'Clinical features of overdose'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vomiting</p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>Coarse muscle tremor</p><p class="bulletIndent2"><span class="glyph">•</span>Seizures</p><p class="bulletIndent2"><span class="glyph">•</span>Hypotensive shock</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac arrhythmias</p><p></p><p class="bulletIndent1">Death typically results from intractable ventricular arrhythmias. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ancillary studies </strong>– Patients with suspected <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning require the following studies (see <a class="local">'Ancillary studies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">Theophylline</a> level; for acute ingestion of a sustained-release or unknown preparation, measure every two hours until it peaks and then every four hours for the first 24 hours</p><p class="bulletIndent2"><span class="glyph">•</span>Serum glucose</p><p class="bulletIndent2"><span class="glyph">•</span>Serum electrolytes</p><p class="bulletIndent2"><span class="glyph">•</span>Serum calcium</p><p class="bulletIndent2"><span class="glyph">•</span>ECG</p><p></p><p class="bulletIndent2">Other studies may also be indicated depending upon the clinical situation as described above. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of acute <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning is suspected in patients with a history of ingestion or access to theophylline and/or clinical findings of overdose including vomiting, agitation, tremors, seizures, tachyarrhythmias, hypotension or hypokalemia with metabolic acidosis. </p><p></p><p class="bulletIndent1">Patients with chronic intoxication may present with few overt symptoms despite a markedly elevated <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> level. Seizures may be the first clinical manifestation of toxicity in these patients. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal decontamination </strong>– For all patients with an acute <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> overdose, we recommend an initial dose of activated charcoal (AC, 1 g/kg, maximum dose 50 g) by mouth or nasogastric tube (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). AC should be withheld in patients who have altered mental status and may not be able to protect their airway, unless endotracheal intubation is performed first. There is no role for gastric emptying (gastric lavage or syrup of ipecac). (See <a class="local">'Gastrointestinal decontamination'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elimination enhancement</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiple-dose activated charcoal (MDAC)</strong> – For patients with signs or symptoms of <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning, we recommend MDAC (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). When administering MDAC, the clinician should avoid inadvertent administration of multiple doses of <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> that can cause life-threatening hypernatremia and severe dehydration. High-dose antiemetic therapy and use of a nasogastric tube are frequently necessary to ensure effective administration. (See <a class="local">'Multiple-dose activated charcoal'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodialysis</strong> – We encourage clinicians to seek advice from a medical toxicologist or regional poison control center when making decisions about the initiation of extracorporeal removal (ECR) in patients with severe <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning (see <a class="local">'Additional resources'</a> above). Whenever possible, start ECR <strong>before</strong> seizures or cardiac arrhythmias develop.</p><p></p><p class="bulletIndent2">For patients with severe life-threatening <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning as described in the table  (<a class="graphic graphic_table graphicRef138597" href="/d/graphic/138597.html" rel="external">table 3</a>), we recommend ECR in addition to MDAC (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). For patients undergoing ECR for theophylline poisoning, we suggest high efficiency hemodialysis rather than hemoperfusion or continuous kidney replacement therapy; charcoal hemoperfusion or CRRT are alternative methods if hemodialysis is not feasible (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Extracorporeal removal'</a> above.)</p><p></p><p class="bulletIndent2">In neonates who are too ill to withstand hemodialysis, hemoperfusion, or continuous kidney replacement therapy, triple volume exchange transfusions in addition to MDAC may be effective. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypokalemia and metabolic acidosis</strong> – Treatment of hypokalemia and metabolic acidosis are rapidly reversed by effective <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> elimination enhancement. We give potassium supplementation (eg, 40 mEq KCL/L in intravenous fluids run at 1 to 1.5 times maintenance) for hypokalemic theophylline poisoned patients with potassium &lt;3 mEq/L or those with ventricular arrhythmias. (See <a class="local">'Hypokalemia and metabolic acidosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent vomiting</strong> – We suggest that patients with <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> poisoning and persistent vomiting receive high-dose <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> (initial dose: 0.15 mg/kg up to 16 mg intravenously) rather than phenothiazines or <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). An ECG should be obtained to screen for a prolonged QTc prior to ondansetron administration. In addition to an antiemetic, we suggest that patients with theophylline poisoning and vomiting receive <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Vomiting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypotension and cardiac arrhythmias</strong> – Initial treatment for hypotension consists of rapid infusion of isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or balanced crystalloid solution such as <a class="drug drug_general" data-topicid="108196" href="/d/drug information/108196.html" rel="external">lactated Ringer</a>. Manage cardiac arrhythmias according to advanced cardiac life support or pediatric advanced life support recommendations  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef129655" href="/d/graphic/129655.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef130747" href="/d/graphic/130747.html" rel="external">algorithm 3</a>). </p><p></p><p class="bulletIndent2">For patients who require continuous infusions of vasoactive medications, we suggest <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> or <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> as first-line therapies (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If shock is refractory to these measures, use of beta-blockers (eg, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> or <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>) in consultation with a medical toxicologist may be effective but requires caution in patients with asthma or chronic obstructive pulmonary disease. <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">Epinephrine</a> and <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> should be avoided. (See <a class="local">'Hypotension'</a> above and <a class="local">'Cardiac arrhythmias'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizures</strong> – Patients with seizures require treatment for status epilepticus as described in the algorithm for children  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 6</a>) and adults  (<a class="graphic graphic_algorithm graphicRef74649" href="/d/graphic/74649.html" rel="external">algorithm 7</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a> and  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/132561.html" rel="external">"Refractory status epilepticus in adults"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Basurto Ona X, Martínez García L, Solà I, Bonfill Cosp X. Drug therapy for treating post-dural puncture headache. Cochrane Database Syst Rev 2011; :CD007887.</a></li><li><a class="nounderline abstract_t">Huber W, Eckel F, Hennig M, et al. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 2006; 239:793.</a></li><li><a class="nounderline abstract_t">Dowden AM, Rullo OJ, Aziz N, et al. Idiopathic systemic capillary leak syndrome: novel therapy for acute attacks. J Allergy Clin Immunol 2009; 124:1111.</a></li><li><a class="nounderline abstract_t">Hurley KF. Does the administration of intravenous aminophylline improve survival in adults with bradyasystolic cardiac arrest? CJEM 2007; 9:26.</a></li><li><a class="nounderline abstract_t">Bordier P. Sleep apnoea in patients with heart failure: part II: therapy. Arch Cardiovasc Dis 2009; 102:711.</a></li><li><a class="nounderline abstract_t">Whitman CB, Schroeder WS, Ploch PJ, Raghavendran K. Efficacy of aminophylline for treatment of recurrent symptomatic bradycardia after spinal cord injury. Pharmacotherapy 2008; 28:131.</a></li><li><a class="nounderline abstract_t">Henkin RI, Velicu I, Schmidt L. An open-label controlled trial of theophylline for treatment of patients with hyposmia. Am J Med Sci 2009; 337:396.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila) 2021; 59:1282.</a></li><li><a class="nounderline abstract_t">Sessler CN. Theophylline toxicity: clinical features of 116 consecutive cases. Am J Med 1990; 88:567.</a></li><li><a class="nounderline abstract_t">Henderson A, Wright DM, Pond SM. Management of theophylline overdose patients in the intensive care unit. Anaesth Intensive Care 1992; 20:56.</a></li><li><a class="nounderline abstract_t">Litovitz TL, Klein-Schwartz W, White S, et al. 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001; 19:337.</a></li><li><a class="nounderline abstract_t">Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009; 47:911.</a></li><li><a class="nounderline abstract_t">Holubek WJ, Hoffman RS, Goldfarb DS, Nelson LS. Use of hemodialysis and hemoperfusion in poisoned patients. Kidney Int 2008; 74:1327.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.</a></li><li><a class="nounderline abstract_t">Pelleg A, Porter RS. The pharmacology of adenosine. Pharmacotherapy 1990; 10:157.</a></li><li><a class="nounderline abstract_t">Pinard E, Riche D, Puiroud S, Seylaz J. Theophylline reduces cerebral hyperaemia and enhances brain damage induced by seizures. Brain Res 1990; 511:303.</a></li><li><a class="nounderline abstract_t">Minton NA, Henry JA. Acute and chronic human toxicity of theophylline. Hum Exp Toxicol 1996; 15:471.</a></li><li><a class="nounderline abstract_t">Kearney TE, Manoguerra AS, Curtis GP, Ziegler MG. Theophylline toxicity and the beta-adrenergic system. Ann Intern Med 1985; 102:766.</a></li><li><a class="nounderline abstract_t">Curry SC, Vance MV, Requa R, Armstead R. The effects of toxic concentrations of theophylline on oxygen consumption, ventricular work, acid base balance, and plasma catecholamine levels in the dog. Ann Emerg Med 1985; 14:554.</a></li><li><a class="nounderline abstract_t">Shannon M. Hypokalemia, hyperglycemia and plasma catecholamine activity after severe theophylline intoxication. J Toxicol Clin Toxicol 1994; 32:41.</a></li><li><a class="nounderline abstract_t">Biberstein MP, Ziegler MG, Ward DM. Use of beta-blockade and hemoperfusion for acute theophylline poisoning. West J Med 1984; 141:485.</a></li><li><a class="nounderline abstract_t">Hendeles L, Jenkins J, Temple R. Revised FDA labeling guideline for theophylline oral dosage forms. Pharmacotherapy 1995; 15:409.</a></li><li><a class="nounderline abstract_t">Lowry JA, Jarrett RV, Wasserman G, et al. Theophylline toxicokinetics in premature newborns. Arch Pediatr Adolesc Med 2001; 155:934.</a></li><li><a class="nounderline abstract_t">Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999; 33:502.</a></li><li><a class="nounderline abstract_t">Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 1998; 18:1112.</a></li><li><a class="nounderline abstract_t">Shannon M. Predictors of major toxicity after theophylline overdose. Ann Intern Med 1993; 119:1161.</a></li><li><a class="nounderline abstract_t">Shannon M, Lovejoy FH Jr. Effect of acute versus chronic intoxication on clinical features of theophylline poisoning in children. J Pediatr 1992; 121:125.</a></li><li><a class="nounderline abstract_t">Bernard S. Severe lactic acidosis following theophylline overdose. Ann Emerg Med 1991; 20:1135.</a></li><li><a class="nounderline abstract_t">McPherson ML, Prince SR, Atamer ER, et al. Theophylline-induced hypercalcemia. Ann Intern Med 1986; 105:52.</a></li><li><a class="nounderline abstract_t">Paloucek FP, Rodvold KA. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med 1988; 17:135.</a></li><li><a class="nounderline abstract_t">Shannon M. Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med 1999; 159:989.</a></li><li><a class="nounderline abstract_t">Titley OG, Williams N. Theophylline toxicity causing rhabdomyolysis and acute compartment syndrome. Intensive Care Med 1992; 18:129.</a></li><li><a class="nounderline abstract_t">Baker MD. Theophylline toxicity in children. J Pediatr 1986; 109:538.</a></li><li><a class="nounderline abstract_t">Amitai Y, Lovejoy FH Jr. Characteristics of vomiting associated with acute sustained release theophylline poisoning: implications for management with oral activated charcoal. J Toxicol Clin Toxicol 1987; 25:539.</a></li><li><a class="nounderline abstract_t">Miura T, Kimura K. Theophylline-induced convulsions in children with epilepsy. Pediatrics 2000; 105:920.</a></li><li><a class="nounderline abstract_t">Covelli HD, Knodel AR, Heppner BT. Predisposing factors to apparent theophylline-induced seizures. Ann Allergy 1985; 54:411.</a></li><li><a class="nounderline abstract_t">O'Riordan JI, Hutchinson J, FitzGerald MX, Hutchinson M. Amnesic syndrome after theophylline associated seizures: iatrogenic brain injury. J Neurol Neurosurg Psychiatry 1994; 57:643.</a></li><li><a class="nounderline abstract_t">Zwillich CW, Sutton FD, Neff TA, et al. Theophylline-induced seizures in adults. Correlation with serum concentrations. Ann Intern Med 1975; 82:784.</a></li><li><a class="nounderline abstract_t">Bahls FH, Ma KK, Bird TD. Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults. Neurology 1991; 41:1309.</a></li><li><a class="nounderline abstract_t">Powell EC, Reynolds SL, Rubenstein JS. Theophylline toxicity in children: a retrospective review. Pediatr Emerg Care 1993; 9:129.</a></li><li><a class="nounderline abstract_t">Bernstein G, Jehle D, Bernaski E, Braen GR. Failure of gastric emptying and charcoal administration in fatal sustained-release theophylline overdose: pharmacobezoar formation. Ann Emerg Med 1992; 21:1388.</a></li><li><a class="nounderline abstract_t">Wiley JF 2nd, Spiller HA, Krenzelok EP, Borys DJ. Unintentional albuterol ingestion in children. Pediatr Emerg Care 1994; 10:193.</a></li><li><a class="nounderline abstract_t">Shannon, M. Theophylline: its rise, demise and resurrection. Clin Ped Emerg Med 2000; 1:213.</a></li><li><a class="nounderline abstract_t">Amitai Y, Yeung AC, Moye J, Lovejoy FH Jr. Repetitive oral activated charcoal and control of emesis in severe theophylline toxicity. Ann Intern Med 1986; 105:386.</a></li><li><a class="nounderline abstract_t">Sage TA, Jones WN, Clark RF. Ondansetron in the treatment of intractable nausea associated with theophylline toxicity. Ann Pharmacother 1993; 27:584.</a></li><li><a class="nounderline abstract_t">Roberts JR, Carney S, Boyle SM, Lee DC. Ondansetron quells drug-resistant emesis in theophylline poisoning. Am J Emerg Med 1993; 11:609.</a></li><li class="breakAll">Shannon MW. Theophylline and caffeine. In: Haddad and Wincehster's Clinical Management of Poisoning and Drug Overdose, Shannon MW, Borron SW, Burns MJ (Eds), Saunders Elsevier, Philadelphia 2007. p.1035.</li><li><a class="nounderline abstract_t">Minton NA, Henry JA. Treatment of theophylline overdose. Am J Emerg Med 1996; 14:606.</a></li><li><a class="nounderline abstract_t">Amin DN, Henry JA. Propranolol administration in theophylline overdose. Lancet 1985; 1:520.</a></li><li><a class="nounderline abstract_t">Bender PR, Brent J, Kulig K. Cardiac arrhythmias during theophylline toxicity. Chest 1991; 39:115.</a></li><li><a class="nounderline abstract_t">Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med 1991; 20:717.</a></li><li class="breakAll">Hoffman RJ. Methylxanthines and selective beta2-adrenergic agonists. In: Goldfrank's Toxicologic Emergencies, 8th, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al (Eds), McGraw-Hill, New York 2006. p.989.</li><li><a class="nounderline abstract_t">Seneff M, Scott J, Friedman B, Smith M. Acute theophylline toxicity and the use of esmolol to reverse cardiovascular instability. Ann Emerg Med 1990; 19:671.</a></li><li><a class="nounderline abstract_t">Blake KV, Massey KL, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 1988; 17:1024.</a></li><li><a class="nounderline abstract_t">Tenenbein M. Position statement: whole bowel irrigation. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997; 35:753.</a></li><li><a class="nounderline abstract_t">Burkhart KK, Wuerz RC, Donovan JW. Whole-bowel irrigation as adjunctive treatment for sustained-release theophylline overdose. Ann Emerg Med 1992; 21:1316.</a></li><li><a class="nounderline abstract_t">Minton NA, Henry JA. Prevention of drug absorption in simulated theophylline overdose. J Toxicol Clin Toxicol 1995; 33:43.</a></li><li><a class="nounderline abstract_t">Berlinger WG, Spector R, Goldberg MJ, et al. Enhancement of theophylline clearance by oral activated charcoal. Clin Pharmacol Ther 1983; 33:351.</a></li><li><a class="nounderline abstract_t">True RJ, Berman JM, Mahutte CK. Treatment of theophylline toxicity with oral activated charcoal. Crit Care Med 1984; 12:113.</a></li><li><a class="nounderline abstract_t">de Vries MH, Rademaker CM, Geerlings C, et al. Pharmacokinetic modelling of the effect of activated charcoal on the intestinal secretion of theophylline, using the isolated vascularly perfused rat small intestine. J Pharm Pharmacol 1989; 41:528.</a></li><li><a class="nounderline abstract_t">Ghannoum M, Wiegand TJ, Liu KD, et al. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila) 2015; 53:215.</a></li><li><a class="nounderline abstract_t">Shannon MW. Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication. Acad Emerg Med 1997; 4:674.</a></li><li><a class="nounderline abstract_t">Shannon M, Wernovsky G, Morris C. Exchange transfusion in the treatment of severe theophylline poisoning. Pediatrics 1992; 89:145.</a></li><li><a class="nounderline abstract_t">Colonna F, Trappan A, de Vonderweid U, Nisi G. Peritoneal dialysis in a 6-weeks old preterm infant with severe theophylline intoxication. Minerva Pediatr 1996; 48:383.</a></li><li><a class="nounderline abstract_t">Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988; 33:735.</a></li><li><a class="nounderline abstract_t">Benowitz, NL, Toffelmire, EB. The use of hemodialysis and hemoperfusion in the treatment of theophylline intoxication. Semin Dial 1993; 6:243.</a></li><li><a class="nounderline abstract_t">Shalkham AS, Kirrane BM, Hoffman RS, et al. The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis 2006; 48:239.</a></li></ol></div><div id="topicVersionRevision">Topic 6501 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21833962" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug therapy for treating post-dural puncture headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714461" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19703708" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Idiopathic systemic capillary leak syndrome: novel therapy for acute attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17391597" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Does the administration of intravenous aminophylline improve survival in adults with bradyasystolic cardiac arrest?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19913772" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sleep apnoea in patients with heart failure: part II: therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18154483" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy of aminophylline for treatment of recurrent symptomatic bradycardia after spinal cord injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19359985" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An open-label controlled trial of theophylline for treatment of patients with hyposmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890263" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189301" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Theophylline toxicity: clinical features of 116 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1609943" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of theophylline overdose patients in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555795" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028214" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18800032" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use of hemodialysis and hemoperfusion in poisoned patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2196534" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The pharmacology of adenosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2334848" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Theophylline reduces cerebral hyperaemia and enhances brain damage induced by seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793529" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acute and chronic human toxicity of theophylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2986507" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Theophylline toxicity and the beta-adrenergic system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3994079" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The effects of toxic concentrations of theophylline on oxygen consumption, ventricular work, acid base balance, and plasma catecholamine levels in the dog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8308948" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hypokalemia, hyperglycemia and plasma catecholamine activity after severe theophylline intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6506685" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Use of beta-blockade and hemoperfusion for acute theophylline poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7479193" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Revised FDA labeling guideline for theophylline oral dosage forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483122" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Theophylline toxicokinetics in premature newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10332544" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Potential metabolic interaction between St. John's wort and theophylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9758323" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239246" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Predictors of major toxicity after theophylline overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1625070" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of acute versus chronic intoxication on clinical features of theophylline poisoning in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1656819" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Severe lactic acidosis following theophylline overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3013062" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Theophylline-induced hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3276248" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation of theophylline overdoses and toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10326941" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Life-threatening events after theophylline overdose: a 10-year prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1613195" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Theophylline toxicity causing rhabdomyolysis and acute compartment syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3746549" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Theophylline toxicity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2895817" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Characteristics of vomiting associated with acute sustained release theophylline poisoning: implications for management with oral activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10819670" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Theophylline-induced convulsions in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3994071" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predisposing factors to apparent theophylline-induced seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201347" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Amnesic syndrome after theophylline associated seizures: iatrogenic brain injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/237450" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Theophylline-induced seizures in adults. Correlation with serum concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1866026" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8346082" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Theophylline toxicity in children: a retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416337" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Failure of gastric emptying and charcoal administration in fatal sustained-release theophylline overdose: pharmacobezoar formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7937293" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Unintentional albuterol ingestion in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Theophylline: its rise, demise and resurrection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3740677" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Repetitive oral activated charcoal and control of emesis in severe theophylline toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8347909" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ondansetron in the treatment of intractable nausea associated with theophylline toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8240564" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ondansetron quells drug-resistant emesis in theophylline poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8240564" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ondansetron quells drug-resistant emesis in theophylline poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857817" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of theophylline overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2857884" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Propranolol administration in theophylline overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cardiac arrhythmias during theophylline toxicity</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2064090" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2064090" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1971502" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Acute theophylline toxicity and the use of esmolol to reverse cardiovascular instability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177989" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482429" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Position statement: whole bowel irrigation. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416325" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Whole-bowel irrigation as adjunctive treatment for sustained-release theophylline overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7837312" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prevention of drug absorption in simulated theophylline overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6337763" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Enhancement of theophylline clearance by oral activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6697727" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of theophylline toxicity with oral activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2571696" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pharmacokinetic modelling of the effect of activated charcoal on the intestinal secretion of theophylline, using the isolated vascularly perfused rat small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25715736" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9223689" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728001" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Exchange transfusion in the treatment of severe theophylline poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8968151" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Peritoneal dialysis in a 6-weeks old preterm infant with severe theophylline intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285069" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Extracorporeal techniques in the treatment of exogenous intoxications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The use of hemodialysis and hemoperfusion in the treatment of theophylline intoxication</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860189" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The availability and use of charcoal hemoperfusion in the treatment of poisoned patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
